Previous studies have shown that src inhibition may heighten gemcitabine cytotoxicity in pancreatic adenocarcinoma cells, indicating combined chemo/signal transduction inhibitor therapy may cause greater growth inhibition and delay emergence of resistance [18, 19]. Here, SRC is linked to pancreatic adenocarcinoma.